Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
These media reports are based on incorrect facts and are without any basis.
The country has constantly worked with the spirit of public-private partnership
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Subscribe To Our Newsletter & Stay Updated
